An observational study in COVID-19 Pandemic and Vitamin D Deficiency, sponsored by Yuksek Ihtisas University. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-21.
Sponsored by Yuksek Ihtisas University · Observational
The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition. In this context, can the protective properties of vitamin D play an important role in this pandemic? brought with it the thought. In this study, it was aimed to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease.
This research was conducted to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease. For this, the approval of the Ministry of Health and then the ethics committee was obtained. For this reason, patients with positive PCR tests and hospitalized patients with vitamin D levels in their biochemistry were included in the study.
The data of the patients were obtained from the medical records. Information such as age, gender, comorbidities, length of hospital stay, vitamin D level were included in the study. According to the statistical analyzes obtained from these data, it has been shown that vitamin D level has no effect on mortality and hospital stay in COVID-19 disease.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 168 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Yuksek Ihtisas University is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with positive COVID-19 PCR (Polymerase Chain Reaction) test and vitamin D level in biochemical parameters, who applied to Ankara City Hospital Neurology-Orthopedics Hospital between 01 August and 31 October 2020.
Exclusion Criteria:
-Patients using drugs that may affect vitamin D absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents
Patients with COVID-19 + and vitamin D levels were included in the study retrospectively. Vitamin D level was categorized into 3 groups as inadequacy, deficiency and normal from medical records. No intervention was made.
Level of Vitamin D
Vitamin D levels of patients with a diagnosis of COVID-10. These results were categorized at the level of deficiency/insufficiency/normal.
Time frame: 1 month later
Relationship between vitamin D level and mortality
Relationship between survival and death by categorized vitamin D level.
Time frame: 1 month later
Relationship between vitamin D level and hospital stay
Length of hospital stay by categorized vitamin D level.
Time frame: 1 month later
Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality
Evaluation of the impact of comorbidities on survival during COVID-19 disease.
Time frame: 1 month later.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yuksek Ihtisas University